# US 2020/0400689 A1 · Methods of treating based on site-specific tau phosphorylation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0400689 A1
- Document ID: US20200400689A1
- Status: Published application
- Kind: A1
- Application number: 17/015,985
- Filed: 2020-09-09
- Published: 2020-12-24
- Earliest claimed: 2018-05-03
- Assignees: Washington University
- Applicants: Washington University
- Inventors: Nicolas Barthelemy; Randall Bateman
- Web page: https://patentgrep.com/patent/US20200400689A1

## CPC

- A61P 25/00: Drugs for disorders of the nervous system
- G01N 33/6896: {Neurological disorders, e.g. Alzheimer's disease}
- G01N 2440/14: phosphorylation
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present disclosure provides methods to quantify tau phosphorylation at specific amino acid residues to predict time to onset of mild cognitive impairment due to Alzheimer's disease, stage Alzheimer's disease, guide treatment decisions, select subjects for clinical trials, and evaluate the clinical efficacy of certain therapeutic interventions.

## Claims

### Claim 1

A method for treating a subject in need thereof, the method comprising
(a) providing an isolated tau sample obtained from the subject and measuring, in the isolated tau sample, tau phosphorylation at T205 and T181, at T205 and T217, or at T205, T181, and T217; and
(b) administering to the subject a pharmaceutical composition to decrease or stabilize the amount of the measured tau phosphorylation in step (a);
wherein the isolated tau sample obtained from the subject contains:
(i) tau phosphorylation at T181 that is about 1.5σ or above and/or tau phosphorylation at T217 that is about 1.5σ or above, and tau phosphorylation at T205 that is below about 1.5σ, or
(ii) tau phosphorylation at T181 that is about 1.5σ or above and/or tau phosphorylation at T217 that is about 1.5σ or above, and tau phosphorylation at T205 that is about 1.5σ or above,
where σ is the standard deviation defined by the normal distribution of tau phosphorylation at the residue measured in a control population without brain amyloid plaques as measured by PET imaging and/or Aβ42/40 measurement in CSF.

### Claim 2 (depends on 1)

The method of claim 1, wherein the isolated tau sample obtained from the subject contains tau phosphorylation at T217 that is above 1.5σ and tau phosphorylation at T205 that is below 1.5σ.

### Claim 3 (depends on 2)

The method of claim 2, wherein (i) tau phosphorylation at T217 is above 1.75σ and tau phosphorylation at T205 is below 1.75σ, (ii) tau phosphorylation at T217 is above 1.8σ and tau phosphorylation at T205 is below 1.8σ, or (iii) tau phosphorylation at T217 is above 1.9σ and tau phosphorylation at T205 is below 1.9σ.

### Claim 4 (depends on 2)

The method of claim 2, wherein tau phosphorylation at T217 is above 2σ and tau phosphorylation at T205 is below 2σ.

### Claim 5 (depends on 1)

The method of claim 1, wherein the isolated tau sample obtained from the subject contains tau phosphorylation at T181 that is above 1.5σ and tau phosphorylation at T205 that is below 1.5σ.

### Claim 6 (depends on 5)

The method of claim 5, wherein (i) tau phosphorylation at T181 is above 1.75σ and tau phosphorylation at T205 is below 1.75σ, (ii) tau phosphorylation at T181 is above 1.8σ and tau phosphorylation at T205 is below 1.8σ, or (iii) tau phosphorylation at T181 is above 1.9σ and tau phosphorylation at T205 is below 1.9σ.

### Claim 7 (depends on 5)

The method of claim 5, wherein tau phosphorylation at T181 is above 2σ and tau phosphorylation at T205 is below 2σ.

### Claim 8 (depends on 1)

The method of claim 1, wherein the isolated tau sample obtained from the subject contains tau phosphorylation at T181 and T217 that is above 1.5σ and tau phosphorylation at T205 that is below 1.5σ.

### Claim 9 (depends on 8)

The method of claim 8, (i) tau phosphorylation at T181 and T217 is above 1.75σ and tau phosphorylation at T205 is below 1.75σ, (ii) tau phosphorylation at T181 and T217 is above 1.8σ and tau phosphorylation at T205 is below 1.8σ, or (iii) tau phosphorylation at T181 and T217 is above 1.9σ and tau phosphorylation at T205 is below 1.9σ.

### Claim 10 (depends on 8)

The method of claim 8, wherein tau phosphorylation at T181 and T217 is above 2σ and tau phosphorylation at T205 is below 2σ.

### Claim 11 (depends on 1)

The method of claim 1, wherein the isolated tau sample obtained from the subject contains tau phosphorylation at T217 and T205 that is above 1.5σ.

### Claim 12 (depends on 11)

The method of claim 11, wherein (i) tau phosphorylation at T217 and T205 is above 1.75σ, (ii) tau phosphorylation at T217 and T205 is above 1.8σ, or (iii) tau phosphorylation at T217 and T205 is above 1.9σ.

### Claim 13 (depends on 11)

The method of claim 11, wherein tau phosphorylation at T217 and T205 is above 2σ.

### Claim 14 (depends on 1)

The method of claim 1, wherein the isolated tau sample obtained from the subject contains tau phosphorylation at T181 and T205 that is above 1.5σ.

### Claim 15 (depends on 14)

The method of claim 14, wherein (i) tau phosphorylation at T181 and T205 is above 1.75σ, (ii) tau phosphorylation at T181 and T205 is above 1.8σ, or (iii) tau phosphorylation at T181 and T205 is above 1.9σ.

### Claim 16 (depends on 14)

The method of claim 14, wherein tau phosphorylation at T181 and T205 is above 2σ.

### Claim 17 (depends on 1)

The method of claim 1, wherein the isolated tau sample obtained from the subject contains tau phosphorylation at T181, T205, and T217 that is above 1.5σ.

### Claim 18 (depends on 17)

The method of claim 17, wherein (i) tau phosphorylation at T181, T205, and T217 is above 1.75σ, (ii) tau phosphorylation at T181, T205, and T217 is above 1.8σ, or (iii) tau phosphorylation at T181, T205, and T217 is above 1.9σ.

### Claim 19 (depends on 17)

The method of claim 17, wherein tau phosphorylation at T181, T205, and T217 is above 2σ.

### Claim 20 (depends on 1)

The method of claim 1, wherein the pharmaceutical composition comprises a cholinesterase inhibitor, an N-methyl D-aspartate (NMDA) antagonist, an antidepressant, a gamma-secretase inhibitor, a beta-secretase inhibitor, an anti-Aβ antibody, an anti-tau antibody, an antagonist of the serotonin receptor σ, a p38alpha MAPK inhibitor, recombinant granulocyte macrophage colony-stimulating factor, a passive immunotherapy, an active vaccine, a tau protein aggregation inhibitor, an anti-inflammatory agent, a phosphodiesterase 9A inhibitor, a sigma-1 receptor agonist, a kinase inhibitor, a phosphatase activator, a phosphatase inhibitor, an angiotensin receptor blocker, a CB1 and/or CB2 endocannabinoid receptor partial agonist, a β-2 adrenergic receptor agonist, a nicotinic acetylcholine receptor agonist, a 5-HT2A inverse agonist, an alpha-2c adrenergic receptor antagonist, a 5-HT 1A and 1D receptor agonist, a glutaminyl-peptide cyclotransferase inhibitor, a selective inhibitor of APP production, a monoamine oxidase B inhibitor, a glutamate receptor antagonist, an AMPA receptor agonist, a nerve growth factor stimulant, a HMG-CoA reductase inhibitor, a neurotrophic agent, a muscarinic M1 receptor agonist, a GABA receptor modulator, a PPAR-gamma agonist, a microtubule protein modulator, a calcium channel blocker, an antihypertensive agent, a statin, or any combination thereof.

### Claim 21 (depends on 1)

The method of claim 1, wherein the pharmaceutical composition comprises a kinase inhibitor.

### Claim 22 (depends on 21)

The method of claim 21, wherein the kinase inhibitor inhibits a thousand-and-one amino acid kinase (TAOK), CDK, GSK-3β, MARK, CDK5, or Fyn.

### Claim 23 (depends on 1)

The method of claim 1, wherein pharmaceutical composition comprises a phosphatase activator.

### Claim 24 (depends on 23)

The method of claim 23, wherein the phosphatase activator increases the activity of protein phosphatase 2A.

### Claim 25 (depends on 1)

The method of claim 1, wherein the isolated tau sample is a composition comprising tau, wherein tau has been purified from blood obtained from a human subject.

### Claim 26 (depends on 1)

The method of claim 1, wherein the isolated tau sample is a composition comprising tau, wherein tau has been purified from cerebrospinal fluid obtained from a human subject.
